ACTRN12612000697886已完成未知
A randomised controlled, 4-way crossover trial, to examine the effects of a high saturated fat, omega-6 fat or carbohydrate meal, on bronchodilator response in adults with stable asthma - Study 2
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Non-smokers, stable asthma. Asthma will be defined by clinical history and airway hyperresponsiveness to hypertonic saline (4.5%) greater than 15% from baseline
排除标准
- •Current smoker, BMI > 35, pregnant or breastfeeding, high blood pressure or cholesterol, history of coronary heart disease, diabetes or currently taking lipid lowering drugs or oral corticosteroids.
研究者
相似试验
进行中（未招募）
不适用
A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalation Powder once-daily (PE capsule via tiotropium/salmeterol HandiHaler®), Tiotropium (18 µg) Inhalation Powder once-daily (via Spiriva® HandiHaler®), Salmeterol (50 µg) Inhalation Powder twice daily (via Multi-Dose Powder Inhaler) and a free combination of Tiotropium (18 µg) Inhalation Powder once-daily (via Spiriva® HandiHaler®) plus Salmeterol (50 µg) Inhalation Powder twice daily (via Multi-Dose Powder Inhaler) following 4-week treatment periods in patients with chronic obstructive pulmonary disease (COPD) - Pharmacokinetics, safety and efficacy of Tiotropium/Salmeterol Inhalation PowderChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2007-000207-15-NLBoehringer Ingelheim bv50
进行中（未招募）
不适用
A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalation Powder once-daily (PE capsule via tiotropium/salmeterol HandiHaler®), Tiotropium (18 µg) Inhalation Powder once-daily (via Spiriva® HandiHaler®), Salmeterol (50 µg) Inhalation Powder twice daily (via Multi-Dose Powder Inhaler) and a free combination of Tiotropium (18 µg) Inhalation Powder once-daily (via Spiriva® HandiHaler®) plus Salmeterol (50 µg) Inhalation Powder twice daily (via Multi-Dose Powder Inhaler) following 4-week treatment periods in patients with chronic obstructive pulmonary disease (COPD) - Pharmacokinetics, safety and efficacy of Tiotropium/Salmeterol Inhalation PowderChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2007-000207-15-BESCS Boehringer Ingelheim Comm.V50
已完成
不适用
Dietary fat, airway inflammation and bronchodilator response in asthma - Study 1Respiratory - AsthmaAsthmaACTRN12611000692932John Hunter Hospital15
暂停
不适用
Myopia Progression and Orthokeratology Lens WearProgressing mild late-onset myopiaEye - Diseases / disorders of the eyeACTRN12606000054516Dr Helen Owens, Senior Lecturer, Department of Optometry, University of Auckland50
进行中（未招募）
不适用
A randomised, controlled, 4-week, cross-over study assessing the efficacy and safety of adding oral morphine IR 10mg or sublingual buprenorphine 0.2mg on demand to a treatment with transdermal buprenorphine 35µg/H in non-malignant chronic low back pain.lumbalgieEUCTR2004-002311-91-BEniversity Hospital Ghent40